Restoring Brain Acetylcholine After Surgery Reverses Memory Loss in Aged Mice
A specific cholinergic brain circuit drives post-surgery memory decline in aging — and reactivating it rescues both cognition and neurogenesis.
Summary
Postoperative cognitive dysfunction (POCD) is a serious and underrecognized complication in older surgical patients. This study in aged mice shows that surgery suppresses a key brain circuit — cholinergic neurons projecting from the medial septum to the hippocampal dentate gyrus — reducing acetylcholine release and shutting down the birth of new neurons. When researchers restored signaling along this pathway, either with the drug galantamine or chemogenetic activation, memory deficits reversed and neurogenesis recovered. The findings pinpoint a specific neural circuit as a causal driver of POCD, suggesting that targeting cholinergic signaling in the hippocampus before or after surgery could protect cognitive function in elderly patients.
Detailed Summary
Postoperative cognitive dysfunction is a well-known but poorly understood condition affecting a substantial proportion of older adults after surgery. Patients experience memory lapses, confusion, and cognitive decline that can persist for months. While cholinergic system disruption has long been implicated, the precise brain circuits responsible have remained unclear — until now.
This study focused on the pathway connecting the medial septum and vertical limb of the diagonal band (MS/vDB) to the dentate gyrus (DG) of the hippocampus, a region central to memory formation and adult neurogenesis. Using aged mice undergoing laparotomy as a POCD model, the researchers tracked what happens to this circuit after surgery.
The results were striking. Surgery reduced both the release of acetylcholine in the hippocampus and the activity of MS/vDB cholinergic neurons, as measured by in vivo fiber photometry. Simultaneously, adult hippocampal neurogenesis — the generation of new neurons in the adult brain — was suppressed, and the mice showed measurable memory deficits.
Critically, restoring signaling along this circuit reversed these effects. Local application of galantamine, an acetylcholinesterase inhibitor already used clinically in Alzheimer's disease, rescued both memory and neurogenesis in the dentate gyrus. Chemogenetic tools showed that sustained — but not acute — activation of the MS/vDB to DG pathway was required to fully restore memory and promote new neuron growth, though acute activation was sufficient to reduce anxiety-like behavior.
These findings establish a causal mechanistic link and carry direct clinical relevance: galantamine is an approved, available medication. The study raises the possibility of perioperative cholinergic support to prevent or treat cognitive decline in elderly surgical patients. Limitations include the animal model and abstract-only access for full methodological detail.
Key Findings
- Surgery suppressed hippocampal acetylcholine release and MS/vDB cholinergic neuron activity in aged mice.
- Postoperative memory deficits were accompanied by reduced adult hippocampal neurogenesis.
- Galantamine applied locally to the dentate gyrus reversed both memory loss and neurogenesis suppression.
- Sustained chemogenetic activation of MS/vDB→DG projections restored memory; acute activation reduced anxiety only.
- The MS/vDB to dentate gyrus cholinergic circuit is causally linked to surgery-induced cognitive decline.
Methodology
Researchers used an aged-mouse laparotomy model to mimic surgical stress. In vivo fiber photometry tracked real-time acetylcholine release and neuronal activity, while chemogenetics (DREADDs) allowed selective activation of the MS/vDB→DG circuit. Neurogenesis was assessed in the dentate gyrus alongside behavioral memory and anxiety tests.
Study Limitations
This study was conducted exclusively in aged mice, and translation to human POCD requires clinical validation. The summary is based on the abstract only, so full methodological details, effect sizes, and neurogenesis quantification methods could not be assessed. The chemogenetic approach used is not yet clinically applicable, and long-term outcomes were not reported.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
